Drug championed by Trump for coronavirus shows no benefit, possible harm in study awaiting validation

Drug championed by Trump for coronavirus shows no benefit, possible harm in study awaiting validation
epa08322528 A box of Chloroquine, or hydroxychloroquine, a well-known antimalarial was seen in a pharmacy in Le Bouscat, near Bordeaux, France, 25 Mars 2020. The French government, through the Health Minister Olivier Veran, has spoken out in favour of more extensive clinical trials that have been carried out at European level in at least seven countries since 22 March. Chloroquine could certainly be administered to patients suffering from severe forms of coronavirus, but only following a strict medical protocol and at the collegial decision of doctors. EPA-EFE/Caroline Blumberg

April 21 (Reuters) - An old malaria drug touted by U.S. President Donald Trump as a "game changer" in the fight against the coronavirus provided no benefit and potentially higher risk of death for patients at U.S. veterans hospitals, according to an analysis that has been submitted for expert review.

There are currently no approved treatments or vaccines specifically for the new coronavirus. But decades old hydroxychloroquine has been widely used in an attempt to alter the course of the COVID-19 respiratory illness based on anecdotal reports that it may provide some benefit.

An analysis of Veterans Health Administration (VA) data found that 28% of 97 patients given hydroxychloroquine along with standard care died, compared with a death rate of 11% for the 158 patients that did not receive the drug. The death rate was 22% for the 113 patients given hydroxychloroquine plus the antibiotic azithromycin.

The research, which has not yet been accepted for publication in a medical journal, is not the result of a clinical trial. It analyzed medical records from 368 men hospitalized with confirmed coronavirus infection at VA centers who died or were discharged by April 11, according to the paper posted online for researchers.

The severe threat posed by the new coronavirus has encouraged sharing within the scientific community of “preprints” – the practice of researchers posting their findings prior to external checks, scrutiny or validation. The study authors did not immediately respond to requests for comment.

After taking patients’ individual characteristics into account, researchers calculated that the risk of death was more than double in those who received hydroxychloroquine.

Hydroxycholoquine also appeared to have no impact on a patients’ need for breathing support. Rates of mechanical ventilation were 13% for those who got the drug versus 14% for patients who received only supportive care. For those who received the malaria drug and the antibiotic, only 7% required breathing assistance.

Even though there is not yet scientific evidence that hydroxychloroquine is effective against COVID-19, doctors have said they are generally comfortable with trying the inexpensive drug, which has also been used to treat lupus and rheumatoid arthritis.

But that may be starting to change. “Some publications in the last week or two have shed doubt on whether hydroxychloroquine is beneficial,” said Dr. Jeremy Falk, a pulmonary specialist at Cedars-Sinai Medical Center in Los Angeles, who was not involved in the VA study.

“We were using it on just about everybody early on. Now we are using it more sparingly.”

Numerous randomized trials are underway in the United States and elsewhere, aiming to answer the question of whether the drug has a role to play in the pandemic that has infected more than 2.5 million people worldwide and killed about 176,000.

(Reporting by Deena Beasley Editing by Bill Berkrot)


"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Please peer review 3 community comments before your comment can be posted

We would like our readers to start paying for Daily Maverick...

…but we are not going to force you to. Over 10 million users come to us each month for the news. We have not put it behind a paywall because the truth should not be a luxury.

Instead we ask our readers who can afford to contribute, even a small amount each month, to do so.

If you appreciate it and want to see us keep going then please consider contributing whatever you can.

Support Daily Maverick→
Payment options